Vivera recognizes the ever-growing needs of those living with central nervous system conditions such as psychiatric, fluency, and neurological disorders, and has set forth to develop novel medications. Vivera is devoted to the research and development of treatments for a variety of conditions within the neuroscience community to enhance the lives of patients and providers.

Our Core Focus:

Central Nervous System Disorders:

Using our novel patented and patent-pending sublingual drug delivery system TABMELT, Vivera seeks to bring new and advanced therapies for some of the most underserved, as well as some of the most widespread, disorders of the central nervous system affecting patients.